Legend Biotech USA Inc
Clinical trials sponsored by Legend Biotech USA Inc, explained in plain language.
Legend Biotech USA is the US arm of Legend Biotech, a cell therapy company known for CAR-T treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …
Phase 1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis early-phase study tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack DLL3, a protein found on certain lung cancer cells. The study includes about 41 adults with advanced small cell lung ca…
Phase 1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC